Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2011 | Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials | SHIH-HUNG YANG ; Kuo Y.-H.; YU-WEN TIEN ; CHIUN HSU ; CHIH-HUNG HSU ; SUNG-HSIN KUO ; ANN-LII CHENG | Oncology | 13 | 13 | |
2016 | Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma | Lin H.-H.; Feng W.-C.; LI-CHUN LU ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer letters | 36 | 39 | |
2005 | Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro | CHIH-HUNG HSU ; Gao M.; Chen C.-L.; Yeh P.-Y.; ANN-LII CHENG | Oncology | 39 | 37 | |
2015 | Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer | Yeh C.-C.; CHIH-HUNG HSU ; YU-YUN SHAO ; Ho W.-C.; MONG-HSUN TSAI ; Feng W.-C.; LU-PING CHOW | Molecular and Cellular Proteomics | 55 | 50 | |
2008 | Intraperitoneal metastasis of hepatocellular carcinoma after spontaneous rupture: A case report | Hung M.-C.; Wu H.-S.; Lee Y.-T.; CHIH-HUNG HSU ; Chou D.-A.; Huang M.-H. | World Journal of Gastroenterology | 33 | 30 | |
2021 | It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade | TSUNG-HAO LIU ; YU-YUN SHAO ; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 7 | 9 | |
2016 | Key opioid prescription concerns in cancer patients: A nationwide study | CHIH-PENG LIN ; CHIH-HUNG HSU ; WEN-MEI FU ; Chen, H. M.; Lee, Y. H.; Lai, M. S.; YU-YUN SHAO | Acta Anaesthesiologica Taiwanica | 10 | 0 | |
2015 | A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer | Chen J.S.; CHIH-HUNG HSU ; Chiang N.J.; Tsai C.S.; Tsou H.H.; Huang S.F.; Bai L.Y.; Chang I.C.; Shiah H.S.; Ho C.L.; Yen C.J.; Lee K.D.; Chiu C.F.; Rau K.M.; Yu M.S.; Yang Y.; Hsieh R.K.; Chang J.Y.; Shan Y.S.; Chao Y.; Chen L.-T.; Chin Y.-H.; Chung T.-R.; Yu W.-L.; Lee M.-H.; Lin L.-F.; Lin P.-C.; Wu Y.-L.; Wang H.-L.; Lu L.-J.; Chen S.-Y.; Wu C.-C.; Wei T.-C.; on behalf of the Taiwan Cooperative Oncology Group | Annals of Oncology | 131 | 115 | |
2011 | Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001 | SUNG-HSIN KUO ; CHIH-HUNG HSU ; Chen L.-T.; YEN-SHEN LU ; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; KUN-HUEI YEH ; ANN-LII CHENG | European Journal of Cancer | 17 | 17 | |
2017 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy | YU-YUN SHAO ; BANG-BIN CHEN ; DA-LIANG OU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; Wang, M. J.; ANN-LII CHENG ; CHIUN HSU | Alimentary Pharmacology and Therapeutics | 10 | 8 | |
2021 | Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy | YING-CHUN SHEN ; Yeh C.-P.; YUNG-MING JENG ; CHIUN HSU ; CHIH-HUNG HSU ; ZHONG-ZHE LIN ; YU-YUN SHAO ; LI-CHUN LU ; TSUNG-HAO LIU ; CHIEN-HUNG CHEN ; ANN-LII CHENG | Cancers | 2 | 2 | |
2014 | Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases | YU-YUN SHAO ; MING-CHIH HO ; ANN-LII CHENG ; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 3 | 3 | |
2005 | Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients | Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; ANN-LII CHENG ; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; CHIH-HUNG HSU ; YEN-SHEN LU ; HWEI-FANG TIEN ; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; PEI-JER CHEN | World Journal of Gastroenterology | 18 | 14 | |
2012 | Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer | LI-CHUN LU ; YU-YUN SHAO ; CHIH-HUNG HSU ; CHIUN HSU ; WEN-FANG CHENG ; YU-LIN LIN ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 0 | | |
2016 | Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; Lee, Ying-Hui; CHIH-HUNG HSU ; ANN-LII CHENG | J. Gastroenterol. Hepatol. | 26 | 24 | |
2010 | Modulation of human UMP/CMP kinase affects activation and cellular sensitivity of deoxycytidine analogs | Liou J.-Y.; Lai H.-R.; CHIH-HUNG HSU ; Chang W.-L.; Hsieh M.-J.; Huang Y.-C.; Cheng Y.-C. | Biochemical Pharmacology | 10 | 10 | |
2022 | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma | Zhu A.X.; Abbas A.R.; de Galarreta M.R.; Guan Y.; Lu S.; Koeppen H.; Zhang W.; CHIH-HUNG HSU ; He A.R.; Ryoo B.-Y.; Yau T.; Kaseb A.O.; Burgoyne A.M.; Dayyani F.; Spahn J.; Verret W.; Finn R.S.; Toh H.C.; Lujambio A.; Wang Y. | Nature Medicine | 108 | 115 | |
2020 | A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy | ZHONG-ZHE LIN ; BANG-BIN CHEN ; Hung, Yi-Ping; HUANG, PO-HSIANG ; Ying-Chun Shen ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG ; Lee, Rheun-Chuan; Chao, Yee; CHIUN HSU | Oncologist | 12 | 10 | |
2007 | Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma | CHIA-CHI LIN ; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIUN HSU ; YU-CHIEH TSAI ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HUNG HSU | Anti-Cancer Drugs | 10 | 8 | |
2017 | National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients | YU-YUN SHAO ; Hsiue E.H.-C.; CHIH-HUNG HSU ; CHIEN-AN YAO ; Chen H.-M.; Lai M.-S.; ANN-LII CHENG | Oncologist | 21 | 17 | |